Here's How Stellantis Is in Even Worse Shape Than Its Rival -- but Clear Upside Remains

Stellantis reported $7.4 billion in warranty expenses in 2025, equal to about 4.4% of revenue, roughly double the industry's historical 2% to 3% norm. The company also posted the second-highest U.S. recall volume at 53, versus Ford's 153, but Stellantis' recalls were more costly and its stock has fallen nearly 60% over three years. Offsetting the quality issues, Stellantis is pursuing a $70 billion turnaround plan, including 11 all-new North American vehicles by 2030 and a 35% regional sales target.

Analysis

The market is treating the Detroit trio as one cyclical bucket, but the earnings sensitivity is diverging sharply. Stellantis is the cleanest expression of a quality-reset story: if warranty intensity stays elevated, every incremental revenue dollar is worth less than at peers because the fix is not just lower SG&A but fewer retroactive cash outflows and less dealer-channel friction. GM looks structurally better positioned because its recall burden is increasingly software-addressable, which is a hidden margin defense that the headline recall count obscures.

The second-order effect is on mix and supplier leverage. Stellantis’ need to refresh North American product at scale likely shifts bargaining power toward suppliers with validated quality systems, embedded electronics, and powertrain reliability data, while legacy commodity suppliers risk being squeezed on price without being able to solve the underlying defect problem. In contrast, GM and, to a lesser extent, Ford can keep spending discipline while letting OTA fixes absorb a larger share of quality issues, which should translate into less warranty drag and steadier free cash flow over the next 4-8 quarters.

The contrarian takeaway is that the market may be over-discounting Stellantis’ turnaround optionality while underestimating the time required to prove it. The stock can rerate only if investors see at least two successive quarters of warranty normalization and evidence that new launches are not creating fresh claims; until then, any rally is likely to be sold as a execution fade. For Ford, the consensus penalty may be slightly overdone because its recall headline count is no longer a clean proxy for cost, but the trend still matters if older-model issues keep bleeding into reported claims into 2026.

Key Decisions for Investors

• Long GM / short STLA as a 6-12 month quality-spread trade: GM has a clearer path to stable warranty expense and better FCF visibility, while STLA still needs proof that the turnaround is translating into claim reduction. Target 15-20% relative performance if STLA fails to show normalization by the next two reporting cycles.
• Hold a tactical underweight in F until recall-related claims trend down for at least two quarters: the cost issue is less severe than the headline count implies, but the stock likely stays range-bound unless management can demonstrate that OTA-heavy remediation is structurally lowering cash costs.
• For event-driven longs, consider STLA call spreads 9-12 months out only if management confirms warranty expense inflection and launch cadence stays on schedule; the risk/reward is attractive only on proof, not anticipation. Stop-loss on any renewed upward revision to warranty guidance.
• Pair long auto software/embedded quality beneficiaries versus auto OEMs with the weakest claims profile, favoring suppliers and test/validation names over pure assembly exposure. The thesis is that OEMs will increasingly outsource quality assurance capability rather than brute-force it internally.
• Avoid chasing a standalone STLA rebound until the next two earnings prints confirm a lower claims run-rate; the catalyst window is months, not days, and the downside remains asymmetric if a new model cycle creates additional defects.